Codexis, Inc. (NASDAQ:CDXS – Get Free Report) major shareholder Opaleye Management Inc. bought 61,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were bought at an average cost of $3.16 per share, with a total value of $192,760.00. Following the completion of the purchase, the insider now directly owns 7,380,000 shares of the company’s stock, valued at approximately $23,320,800. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Codexis Stock Performance
Shares of NASDAQ:CDXS opened at $3.21 on Friday. Codexis, Inc. has a 52 week low of $1.45 and a 52 week high of $4.91. The stock has a market capitalization of $226.49 million, a P/E ratio of -3.45 and a beta of 2.07. The firm has a fifty day simple moving average of $3.11 and a two-hundred day simple moving average of $3.20. The company has a quick ratio of 2.92, a current ratio of 2.99 and a debt-to-equity ratio of 0.46.
Codexis (NASDAQ:CDXS – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06). Codexis had a negative return on equity of 64.06% and a negative net margin of 125.41%. The business had revenue of $7.98 million during the quarter, compared to analysts’ expectations of $7.64 million. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, analysts expect that Codexis, Inc. will post -0.75 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Codexis
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on CDXS shares. Benchmark cut shares of Codexis from a “buy” rating to a “hold” rating in a research note on Monday, August 19th. Jefferies Financial Group began coverage on shares of Codexis in a research note on Monday, June 3rd. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of Codexis in a research note on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.75.
Check Out Our Latest Report on CDXS
About Codexis
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
See Also
- Five stocks we like better than Codexis
- Where to Find Earnings Call Transcripts
- 3 Dividend-Yielding Stocks Too Cheap to Pass Up
- How to Most Effectively Use the MarketBeat Earnings Screener
- Triple Witching: The Market’s Quarterly Rollercoaster
- What Do S&P 500 Stocks Tell Investors About the Market?
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.